Oryx’s oncolytic virus treatment for the aggressive form of brain cancer, glioblastoma, has demonstrated safety and efficacy in a clinical trial.

Oryx is developing three exciting candidates for the treatment of cancer. One of these, an oncolytic virus, ParvOryx, has demonstrated its safety and efficacy in patients with glioblastoma – a particularly aggressive form of brain cancer. The Phase I/IIa results, published in Molecular Therapy, showed that the treatment safely improved patient survival and support its progression through the clinic.

More info:  https://labiotech.eu/brain-cancer-oncolytic-virus-oryx/